C4 Therapeutics, Inc. announced that it has entered into an agreement to issue 5,567,928 shares at an issue price of $4.49 per share for the gross proceeds of $24,999,996.72 on May 30, 2023. The transaction will include participation from new investor, Betta Pharmaceuticals Co., Ltd. The transaction is to be completed following the receipt of required regulatory approvals and other customary closing conditions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.17 USD | -1.12% | -8.18% | +9.20% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
40.54 CNY | +3.66% | +12.49% | 2.34B | ||
6.17 USD | -1.12% | -8.18% | 423M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.20% | 423M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CCCC Stock
- News C4 Therapeutics, Inc.
- C4 Therapeutics, Inc. announced that it expects to receive $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.